Market reactionShares fell 11% on Nov 5.
Eledon Pharmaceuticals is a clinical-stage company developing tegoprubart, an anti-CD40L antibody to prevent organ rejection after kidney and islet cell transplants; it is not approved.
Eledon's case is that tegoprubart can prevent kidney transplant rejection as well as tacrolimus while protecting kidney function. BESTOW missed its primary kidney-function endpoint, but longer follow-up showed higher kidney function. Patient-reported benefits add support. Eledon plans a global Phase 3 trial after a successful FDA meeting, with islet transplantation offering another development opportunity. Management expects cash to fund operations into the second quarter of 2027, but the filing identifies substantial going-concern doubt and a need for additional financing.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: LEGACY Phase 3 starts and is funded
Does Eledon initiate LEGACY with financing sufficient to carry out the planned trial?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Patient-reported benefits support tegoprubart; pivotal trial funding remains the key hurdle
Tacrolimus challenger with cleaner safety profile heads into Phase 3, but runway expires before trial reads out
Tegoprubart's Phase 3 kidney transplant path hinges on whether FDA accepts a non-inferiority safety profile after BESTOW missed its primary efficacy endpoint
Tegoprubart's Phase 3 path in kidney transplant hinges on FDA accepting a composite endpoint after the Phase 2 primary eGFR endpoint miss
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Kidney diseases, Liver and digestive diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
8 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.